Zolantidine
![]() | |
| Clinical data | |
|---|---|
| ATC code | None |
| Identifiers | |
| |
| CAS Number | 104076-38-2 |
| PubChem (CID) | 91769 |
| ChemSpider | 82866 |
| UNII |
M1108XAY01 |
| ChEMBL | CHEMBL419296 |
| Chemical and physical data | |
| Formula | C22H27N3OS |
| Molar mass | 381.5 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Zolantidine is a brain-penetrating selective histamine H2 receptor (HRH2) antagonist developed by Smith, Kline & French, with the research code of SK&F 95282. It is a benzthiazole derivative with a 30-fold higher potency for H2 receptors than other peripheral and central receptors.[1]
References
- ↑ Calcutt, CR; Ganellin, CR; Griffiths, R; Leigh, BK; Maguire, JP; Mitchell, RC; Mylek, ME; Parsons, ME; Smith, IR; Young, RC (January 1988). "Zolantidine (SK&F 95282) is a Potent Selective Brain-penetrating Histamine H2-receptor Antagonist". British Journal of Pharmacology. 93 (1): 69–78. doi:10.1111/j.1476-5381.1988.tb11406.x. PMC 1853786
. PMID 2894879.
This article is issued from Wikipedia - version of the 8/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
